Login to Your Account

Pharma: Other News To Note

Monday, February 27, 2012

Forest Laboratories Inc., of New York, said it received European approval to market Colobreathe (dry powder colistimethate sodium for inhalation) for treating cystic fibrosis patients, ages 6 and older, with chronic lung infections caused by P. aeruginosa.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription